Trial reportActa orthopaedica2025
Total shoulder arthroplasty for glenohumeral osteoarthritis leads to better outcomes than hemiarthroplasty at a minimum 5 years: an intraoperative randomization-controlled trial of 79 patients.
Trial report in Acta orthopaedica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01288066 (A Randomized Multicenter Study Comparing the Effectiveness of Hemi Versus Total Shoulder Arthroplasty in Patients With a Degenerative Joint Disease), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Multicenter Study Comparing the Effectiveness of Hemi Versus Total Shoulder Arthroplasty in Patients With a Degenerative Joint Disease
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeIt is unclear whether total shoulder arthroplasty (TSA) results in better outcomes in patients with degenerative shoulder diseases compared with hemiarthroplasty (HA). This randomized controlled trial (NCT01288066) is an international, multicenter study with the primary aim to assess pain and shoulder joint function at 5-year follow-up in adults surgically treated with TSA or HA.
methodsThe inclusion criteria were patients aged 18 and older with primary or secondary osteoarthritis, with a functionally intact rotator cuff and glenoid morphology of Walch type A1, A2, or B1. Randomization to either TSA or HA occurred intraoperatively after full surgical preparation for glenoid prosthetic implantation in all patients. The primary outcome measure was the Constant-Murley scores (CMS) at 5-year follow-up. Secondary outcomes were patient-reported outcomes (Shoulder Pain and Disability Index [SPADI], EQ-5D, and EQ VAS), adverse events, and implant survivorship at 5-year follow-up.
resultsThere were 79 patients eligible, of whom 40 and 39 patients were randomized to receive TSA or HA, respectively. The dropout rate at 5 years was 34% due to 27 of 79 patients withdrawing consent or being lost to follow-up. The mean CMS improved from preoperative to 5 years' follow-up for both TSA and HA treatment groups. At 5 years, the TSA group had a significantly better mean CMS (77, 95% confidence interval [CI] 72-82) than the HA group (65, CI 57-73). The mean treatment difference was 12 (Cl 2.8-22; P = 0.01). The adverse event rate and relative risk of revision were not significantly different between the groups.
conclusionIn patients with glenohumeral osteoarthritis randomized to either TSA or HA, TSA was the favorable approach based on less pain and better joint function 5 years after surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.